XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest

XOMA Royalty Corp

Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.
XOMA gets low- to mid-single-digit net royalty on seralutinib commercial sales.
XOMA retains up to $25M of future milestone payments tied to seralutinib.
Seralutinib (Phase 3 PAH) readout expected Q4 2025; developed by Gossamer/Chiesi.
This is XOMA's second whole-company acquisition in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.